Myc Proto Oncogene Protein drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Oncology, Metabolic Disorders, and Undisclosed which include the indications Unspecified Cancer, Solid Tumor, Unspecified Metabolic Disorders, and Unspecified. It also reviews key players involved in Myc Proto Oncogene Protein targeted therapeutics development with respective active and dormant or discontinued products.

The Myc Proto Oncogene Protein pipeline targets constitutes close to 40 molecules. Out of which, approximately 34 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 2, 1, 15, and 16 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 3 molecule.

Myc Proto Oncogene Protein overview

Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.

For a complete picture of Myc Proto Oncogene Protein’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.